sCLEC-2 (Soluble C-Type Lectin-like Receptor 2) as a New Diagnostic Marker of Platelet Activation in Colorectal Cancer Patients—A Preliminary Study
Diagnostics · 26.03.2026 · 16 (7) · 1004
DOI: 10.3390/diagnostics16071004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 26.03.2026. Verfasst von Violetta Dymicka-Piekarska und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, Waszyngtona 15a St., 15-269 Białystok, Poland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Bialystok.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: CLEC-2 (C-type lectin-like receptor 2), the newest discovered platelet receptor, is involved in platelet activation and aggregation, the inflammatory response, tumor growth, metastasis, and angiogenesis. These unique features make CLEC-2 a promising candidate for a new biomarker and therapeutic target. The aim of our study was to evaluate the diagnostic value of CLEC-2 in patients with colorectal cancer (CRC).
Methods
The serum CLEC-2 concentration was determined using ELISA methods in 64 CRC patients and 25 healthy subjects.
Results
Our results indicate that the concentration of the serum CLEC-2 was significantly higher in CRC patients than in healthy subjects. Furthermore, the CLEC-2 levels were significantly higher in G3- than G2-grade CRC, and in patients with more advanced CRC, such as those with lymph node and distant metastases, than in patients without any metastases. CLEC-2 showed a positive correlation with platelet indices (PLT and MPV). The area under the ROC curve confirmed CLEC-2’s excellent diagnostic power in distinguishing between patients with CRC.
Conclusions
Our results indicate that CLEC-2 may be associated with CRC development and suggest that the identification of this biomarker could be useful for determining CRC progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, Waszyngtona 15a St., 15-269 Białystok, Poland.
- 1st Department of General and Endocrine Surgery, Medical University of Bialystok, M. Skłodowskiej-Curie 24a St, 15-276 Białystok, Poland.
- Department of Biostatistics and Medical Informatics, Medical University of Bialystok, Szpitalna 37, 15-295 Białystok, Poland.
- Department of Psychology and Sociology of Health and Public Health, University of Warmia and Mazury in Olsztyn, Warszawska 30, 10-082 Olsztyn, Poland.
ORCID-Profile: Anna Justyna Milewska, Blanka Wolszczak-Biedrzycka, Maja Aleksandra Oksentowicz, Justyna Dorf
Förderung
- Medical University of Bialystok
Zitieren
APA
Dymicka-Piekarska, V., Gryko, M., Milewska, A. J., Wolszczak-Biedrzycka, B., Oksentowicz, M. A., Motybel-Iwańczuk, E., Pawlak, P., & Dorf, J. (2026). sCLEC-2 (Soluble C-Type Lectin-like Receptor 2) as a New Diagnostic Marker of Platelet Activation in Colorectal Cancer Patients—A Preliminary Study. Diagnostics, 16(7), 1004. https://doi.org/10.3390/diagnostics16071004
Vancouver
Dymicka-Piekarska V, Gryko M, Milewska AJ, Wolszczak-Biedrzycka B, Oksentowicz MA, Motybel-Iwańczuk E, et al. sCLEC-2 (Soluble C-Type Lectin-like Receptor 2) as a New Diagnostic Marker of Platelet Activation in Colorectal Cancer Patients—A Preliminary Study. Diagnostics. 2026;16(7):1004. doi:10.3390/diagnostics16071004
BibTeX
@article{DymickaPiekarska2026,
author = {Dymicka-Piekarska, Violetta and Gryko, Mariusz and Milewska, Anna Justyna and Wolszczak-Biedrzycka, Blanka and Oksentowicz, Maja Aleksandra and Motybel-Iwańczuk, Elżbieta and Pawlak, Paweł and Dorf, Justyna},
title = {sCLEC-2 (Soluble C-Type Lectin-like Receptor 2) as a New Diagnostic Marker of Platelet Activation in Colorectal Cancer Patients—A Preliminary Study},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {7},
pages = {1004},
doi = {10.3390/diagnostics16071004}
}
EUVIMED